Cleveland Clinic releases their annual list of highly promising innovations.
Public Citizen tells FDA it should withdraw draft guidance that it believes will allow drugmakers to tell physicians marketed drugs are less risky than their labels indicate.
Orphan drug growth will easily outpace non-orphans through 2020.
Programmatic ad buying hasn't exactly taken over the industry, but its approach has precipitated a paradigm shift, media experts say.
Sanofi courts AstraZeneca CEO Soriot; Teva CEO optimistic on Copaxone patent ruling; AstraZeneca scores approval of diabetes combo drug.
The country's drug ministry has identified drugs as an area for savings.
The company unveils a plan for deploying controllable nanoparticles into peoples' bodies for monitoring health conditions.
Herper writes that Sanofi—without Viehbacher—is at risk of moving too slowly in an increasingly competitive industry.
Widely used plastics such as PET will have to be replaced with more costly glass containers.
The former FDA director of medical device compliance has petitioned the agency to make oral contraceptives over-the-counter.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.